IRLAB Therapeutics AB
STO:IRLAB A

Watchlist Manager
IRLAB Therapeutics AB Logo
IRLAB Therapeutics AB
STO:IRLAB A
Watchlist
Price: 12.6 SEK -1.95% Market Closed
Market Cap: 652.5m SEK
Have any thoughts about
IRLAB Therapeutics AB?
Write Note

P/E
Price to Earnings

-5.5
Current
-3
Median
22.3
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-5.5
=
Market Cap
653.5m SEK
/
Net Income
-119.5m SEK
All Countries
Close
Earnings Growth
SE
IRLAB Therapeutics AB
STO:IRLAB A
Average P/E: 35.1
Negative Multiple: -5.5
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
94.2
454%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
37.5
89%
US
Johnson & Johnson
NYSE:JNJ
26.2
-22%
US
Merck & Co Inc
NYSE:MRK
18.9
7 426%
CH
Roche Holding AG
SIX:ROG
18.6
30%
UK
AstraZeneca PLC
LSE:AZN
34.3
175%
CH
Novartis AG
SIX:NOVN
13.1
19%
US
Pfizer Inc
NYSE:PFE
37.7
712%

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-7.4
2-Years Forward
P/E
-51.5
3-Years Forward
P/E
-5.5

See Also

Discover More